These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18535288)

  • 1. MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.
    Flanagan SA; Krokosky CM; Mannava S; Nikiforov MA; Shewach DS
    Mol Pharmacol; 2008 Sep; 74(3):863-71. PubMed ID: 18535288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short hairpin RNA suppression of thymidylate synthase produces DNA mismatches and results in excellent radiosensitization.
    Flanagan SA; Cooper KS; Mannava S; Nikiforov MA; Shewach DS
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):e613-20. PubMed ID: 22867891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells.
    Robinson BW; Im MM; Ljungman M; Praz F; Shewach DS
    Cancer Res; 2003 Oct; 63(20):6935-41. PubMed ID: 14583494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.
    Davis TW; Wilson-Van Patten C; Meyers M; Kunugi KA; Cuthill S; Reznikoff C; Garces C; Boland CR; Kinsella TJ; Fishel R; Boothman DA
    Cancer Res; 1998 Feb; 58(4):767-78. PubMed ID: 9485033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization.
    McGinn CJ; Miller EM; Lindstrom MJ; Kunugi KA; Johnston PG; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):851-9. PubMed ID: 7960987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers.
    Flanagan SA; Robinson BW; Krokosky CM; Shewach DS
    Mol Cancer Ther; 2007 Jun; 6(6):1858-68. PubMed ID: 17575114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells.
    Bruso CE; Shewach DS; Lawrence TS
    Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1411-7. PubMed ID: 2148170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo.
    Lawrence TS; Davis MA; McKeever PE; Maybaum J; Stetson PL; Normolle DP; Ensminger WD
    Cancer Res; 1991 Aug; 51(15):3900-5. PubMed ID: 1830239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells.
    Yan T; Seo Y; Kinsella TJ
    Clin Cancer Res; 2009 Nov; 15(22):6912-20. PubMed ID: 19861440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
    Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
    Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of dependence of 5-fluorodeoxyuridine-mediated radiosensitization on cytotoxicity.
    Lawrence TS; Davis MA; Chang EY; Canman CE; Maybaum J; Radany EH
    Radiat Res; 1995 Sep; 143(3):281-5. PubMed ID: 7652165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression.
    Lawrence TS; Davis MA; Tang HY; Maybaum J
    Int J Radiat Biol; 1996 Sep; 70(3):273-80. PubMed ID: 8800198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
    Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
    Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
    Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
    Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
    Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
    Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
    Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
    Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage.
    Meyers M; Wagner MW; Mazurek A; Schmutte C; Fishel R; Boothman DA
    J Biol Chem; 2005 Feb; 280(7):5516-26. PubMed ID: 15611052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.